Related Experiment Video
Updated: Aug 4, 2026
05:54
Operation Procedure and Precautions of Thread-Embedding Acupuncture Therapy in Alzheimer
Published on: May 10, 2024
Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018
B Vellas1, L J Bain, J Touchon
1B. Vellas, INSERM U1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France.
The Journal of Prevention of Alzheimer'S Disease
|May 8, 2019
Summary
The 2018 Clinical Trials on Alzheimer's Disease conference highlighted lessons from treatment successes and failures. Future Alzheimer's disease clinical trials will incorporate these insights and novel therapeutic strategies.
Area of Science:
- Neuroscience
- Clinical Research
- Pharmacology
Background:
- The 2018 Clinical Trials on Alzheimer's Disease (CTAD) conference convened to discuss Alzheimer's disease (AD) treatment trials.
- Both successful and unsuccessful trial outcomes were presented, offering valuable learning opportunities.
Purpose of the Study:
- To share insights gained from AD clinical trials to improve future study designs.
- To present data on novel and non-amyloid therapeutic strategies for Alzheimer's disease.
- To introduce new tools for enhancing clinical trial efficiency and predictive modeling.
Main Methods:
- Review of recent Alzheimer's disease clinical trial data.
- Presentation of findings from neuroprotective, regenerative, neuroinflammatory, and synaptic function-targeting strategies.
- Discussion of novel biomarkers and machine learning algorithms for predictive modeling in clinical trials.
Main Results:
- Key learnings from both successes and failures in AD drug development were shared.
- Emerging therapeutic approaches beyond amyloid targets were explored.
- Advancements in biomarkers and computational tools for trial optimization were highlighted.
Conclusions:
- Lessons learned from past trials are crucial for designing more effective future Alzheimer's disease studies.
- A multifaceted approach, including novel therapeutics and advanced tools, is needed to combat Alzheimer's disease.
- Improved methodologies, including biomarkers and machine learning, can enhance the success rate of clinical trials.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...